The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 first-in-human study of XMT-1107, a polymer-conjugated fumagillol derivative, in patients (pts) with advanced solid tumors.
Johanna C. Bendell
Research Funding - Mersana Therapeutics
Geoffrey Shapiro
Research Funding - Mersana Therapeutics
Edward A. Sausville
Research Funding - Mersana Therapeutics
Suzanne Fields Jones
Research Funding - Mersana Therapeutics
John Frederick Hilton
Research Funding - Mersana Therapeutics
Dana Shkolny
Consultant or Advisory Role - Mersana Therapeutics
Stock Ownership - Mersana Therapeutics
Burkhard Blank
Consultant or Advisory Role - Mersana Therapeutics
Stock Ownership - Mersana Therapeutics
Donald Alan Bergstrom
Employment or Leadership Position - Mersana Therapeutics
Stock Ownership - Mersana Therapeutics